(Total Views: 583)
Posted On: 12/29/2020 5:28:27 PM
Post# of 154883
CGC,
Cytodyn is currently running and open label 2b/3 HIV monotherapy.
This may be a great design for longhaulers if an initial trial proves successful.
https://clinicaltrials.gov/ct2/show/NCT028599...amp;rank=9
Trial design,
terventional (Clinical Trial)
Estimated Enrollment :
500 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Phase 2b/3, Multicenter Study to Assess the Treatment Strategy of Using PRO 140 SC as Long-Acting Single-Agent Maintenance Therapy for 48 Weeks in Virologically Suppressed Subjects With CCR5-tropic HIV-1 Infection
Cytodyn is currently running and open label 2b/3 HIV monotherapy.
This may be a great design for longhaulers if an initial trial proves successful.
https://clinicaltrials.gov/ct2/show/NCT028599...amp;rank=9
Trial design,
terventional (Clinical Trial)
Estimated Enrollment :
500 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Phase 2b/3, Multicenter Study to Assess the Treatment Strategy of Using PRO 140 SC as Long-Acting Single-Agent Maintenance Therapy for 48 Weeks in Virologically Suppressed Subjects With CCR5-tropic HIV-1 Infection
(2)
(0)
